Relief Therapeutics Holding AG (RLFTF)

[mc67]

From Ya-h-o 5hrs ago

Coz 5 hours ago

Thank you for your email.

We understand that it is difficult to sort through the various news sources to find the truth.

As we have reported, our Phase 2b/3 trial passed the first interim analysis (which included an unblinded futility assessment) with positive results and a second interim analysis is slated to occur imminently, involving roughly two-thirds of the target number of patients to be enrolled (i.e., 102 out of a total 165 subjects).

Furthermore, we have released data with our partner NeuroRx Inc. from the Expanded Access Program (EAP) with RLF-100 showing very intriguing clinical efficacy data in extremely critically ill COVID-19 patients (i.e., those with no other treatment options, who have been on ventilators or ECMO for extended periods of time) in whom none of the existing approved or experimental drugs have been shown to work at all.

This gives us substantial confidence in the outcome of our ongoing Phase 2b/3 trial with the IV formulation of the drug.

As soon as we have new information from the trial, we will share it with the market and all stakeholders promptly.

We wish you and your loved ones continued health.

Kind regards,
Brittney Sojeva